Checkpoint inhibitors in lung cancer: latest developments and clinical potential

Schvartsman, Gustavo; Ferrarotto, Renata; Massarelli, Erminia

doi:10.1177/1758834016661164

Cited by 32 publications

(19 citation statements)

References 70 publications

(110 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…These agents target molecular pathways orchestrated by the programmed cell death protein-1 (PD-1)/ programmed cell death ligand-1 (PD-L1) interaction. PD-L1 expression is directly involved in evasion of the immune response by cancer cells [10]. Its binding to the PD-1 receptor on T cells promotes a dual inhibition mechanism: firstly, by inducing apoptosis in antigen-specific T cells and secondly, by simultaneously reducing regulatory T cell (Treg) apoptosis.…”

Section: Mirnas As Key Modulators Of Tumour Immune Response In Lung Cmentioning

confidence: 99%

“…Several programmed death-1 (PD-1) and programmed death ligand-1 (PD-L1) inhibitors have been approved by the Food and Drug Administration (FDA) to treat metastatic NSCLC. Still, many questions remain to be addressed on immunotherapy, regarding the optimal schedule of treatment, identifying proper predictive biomarkers and co-targeting of the other key modulators of tumour immune response [10]. Recently, various miRNAs have been found to target key cancer-related immune pathways, which seem involved in the secretion of immunosuppressive or immunostimulating factors by cancer or immune cells [11].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

miRNAs as Biomarkers and Therapeutic Targets in Non-Small Cell Lung Cancer: Current Perspectives

Florczuk¹,

Szpechcinski²,

Chorostowska‐Wynimko³

2017

Targ Oncol

View full text Add to dashboard Cite

Lung cancer is the most common cancer worldwide. Up to 85% of lung cancer cases are diagnosed as nonsmall cell lung cancer (NSCLC). The effectiveness of NSCLC treatment is expected to be improved through the implementation of robust and specific biomarkers. MicroRNAs (miRNAs) are small, non-coding molecules that play a key role in the regulation of basic cellular processes, including differentiation, proliferation and apoptosis, by controlling gene expression at the post-transcriptional level.

show abstract

Section: Mirnas As Key Modulators Of Tumour Immune Response In Lung Cmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

miRNAs as Biomarkers and Therapeutic Targets in Non-Small Cell Lung Cancer: Current Perspectives

Florczuk¹,

Szpechcinski²,

Chorostowska‐Wynimko³

2017

Targ Oncol

View full text Add to dashboard Cite

show abstract

“…Of the lung cancer cases diagnosed, ~85% are non-small cell lung cancer (NSCLC), which has a poor prognosis and is difficult to treat (2). Despite years of research (3,4), the survival rate of patients with NSCLC remains poor. Therefore, understanding the pathogenesis of lung cancer is important to those patients with NSCLC.…”

Section: Introductionmentioning

confidence: 99%

Overexpression of CXCR4 promotes invasion and migration of non‑small cell lung cancer via EGFR and MMP‑9

Zuo

Wen

et al. 2017

Oncol Lett

View full text Add to dashboard Cite

Abstract. The aim of the present study was to verify whether overexpression of CXC receptor 4 (CXCR4) promotes the invasion and migration of non-small cell lung cancer (NSCLC) via epidermal growth factor receptor (EGFR) and matrix metallopeptidase-9 (MMP-9), and to detect the association between CXCR4, EGFR and MMP-9. The effects of overexpression of CXCR4 on lung cancer cell functions were investigated by migration and invasion assays. Western blotting and zymograph assays were used to analyze the protein expression levels of EGFR and the production of MMP-9, respectively. Immunohistochemistry was applied to analyze the expression of EGFR, CXCR4 and MMP-9 in NSCLC. Statistical analyses were used to detect the associations among EGFR, CXCR4 and MMP-9 in NSCLC. Finally, survival analyses were performed. CXCR4 overexpression enhanced cell motility and invasion. CXCR4 also promoted expression of EGFR and elevated MMP-9 production. CXCR4, EGFR and MMP-9 were highly expressed in NSCLC, and were not identified as associated with age and sex (P>0.05). However, they were associated with tumor differentiation and lymph node metastasis (P<0.05). CXCR4, EGFR and CXCR4 expression were positively associated with one another in NSCLC (P<0.05). In addition, patients with positive expression of CXCR4, EGFR or MMP-9 in tumors exhibited significantly shorter overall survival compared with those with negative expression (P<0.05). In conclusion, CXCR4 overexpression enhanced cell motility and invasion via EGFR and MMP-9. CXCR4, EGFR and MMP-9 were identified as highly expressed in NSCLC, and there was positive correlation among them.

show abstract

“…Monoklonální protilátky proti CTLA-4 a PD-1 nebo PD-L1 jsou intenzivně zkoumány a postupně nachá-zejí uplatnění v léčbě různých malignit, vč. plicního karcinomu [2][3][4][5]16]. …”

Section: Checkpoint Inhibitoryunclassified

Immunotherapy in the Treatment of Lung Cancer

Fiala¹,

Šorejs²,

Pešek³

et al. 2017

Klin Onkol

View full text Add to dashboard Cite

1 Onkologická a radioterapeutická klinika LF UK a FN Plzeň 2 Biomedicínské centrum LF UK v Plzni 3 Klinika pneumologie a ftizeologie LF UK a FN Plzeň Souhrn Východiska: Karcinom plic zaujímá přední místa v incidenci i mortalitě nádorových onemocnění celosvětově, i v České republice. Přes významné pokroky v systémové onkologické léčbě dosažené v poslední době patří plicní karcinom mezi zhoubné nádory s nejhorší prognózou a potřeba hledání inovativních terapeutických prostředků a metod je zde stále velmi vysoká. Imunoterapie představuje dynamicky se rozvíjející oblast systémové onkologické léčby, která se v poslední době začíná významně uplatňovat i u pa cientů s plicním karcinomem. Nejlépe využitelný typ imunoterapie v současné době představují checkpoint inhibitory, kam patří CTLA-4 inhibitory (ipilimumab a tremelimumab) a PD-1/ PD-L1 inhibitory (nivolumab, pembrolizumab, durvalumab a avelumab). Mimo monoterapie jsou zkoumány i jejich různé kombinace nebo kombinace s chemoterapií nebo cílenou léčbou. Protinádorové vakcíny ani cytokiny nenalezly v léčbě plicního karcinomu větší význam, přesto, že zde byly zkoumány. Checkpoint inhibitory ukazují příznivé výsledky zejména v léčbě pa cientů s pokročilým stadiem (stadium IIIB a IV) nemalobuněčného karcinomu plic (non-small cell lung carcinoma -NSCLC) a jsou intenzivně zkoumány i u pa cientů s malobuněčným karcinomem plic (small cell lung carcinoma -SCLC). Cíl: Cílem této přehledové práce bylo sumarizovat nejvýznamnější dosažené poznatky o výsledcích, možnostech a perspektivách moderní imunoterapie v léčbě pa cientů s karcinomem plic. Závěr: Imunoterapie představuje významný směr moderní onkologické léčby a pro pa cienty s plicním karcinomem přináší naději na prodloužení života a zlepšení jeho kvality. Klíčová slova imunoterapie -karcinom plic -NSCLC -SCLC -checkpoint inhibitory AbstractBackground: Lung cancer occupies the leading position of cancer incidence and mortality worldwide, including in the Czech Republic. Despite significant advances in systemic oncology treatments, lung cancer still has the worst prognosis, which is driving the need for innovative therapies and methods to treat this disease. Immunotherapy is a developing area of systemic oncology treatment, which has recently begun to be significantly applied to patients with lung carcinoma. The most useful type of immunotherapy currently employs checkpoint inhibitors, including CTLA-4 inhibitors (ipilimumab and tremelimumab) and PD-1/PD-L1 inhibitors (nivolumab, pembrolizumab, durvalumab, and avelumab). Except for monotherapy, different combinations of these inhibitors or combinations between one more of these inhibitors and chemotherapy or targeted treatment are being actively studied. Despite intensive investigations, anti-tumor vaccines and cytokines have not had an important impact on the treatment of lung cancer. Checkpoint inhibitors have yielded favorable results, especially for the treatment of advanced (i.e., stage IIIB and IV) non-small cell lung cancer (NSCLC) and are being extensively investig...

show abstract

Checkpoint inhibitors in lung cancer: latest developments and clinical potential

Cited by 32 publications

References 70 publications

miRNAs as Biomarkers and Therapeutic Targets in Non-Small Cell Lung Cancer: Current Perspectives

miRNAs as Biomarkers and Therapeutic Targets in Non-Small Cell Lung Cancer: Current Perspectives

Overexpression of CXCR4 promotes invasion and migration of non‑small cell lung cancer via EGFR and MMP‑9

Immunotherapy in the Treatment of Lung Cancer

Contact Info

Product

Resources

About